Our findings demonstrate that intravenous dantrolene, a drug used to treat another ryanodine receptor disorder, malignant hyperthermia, abolished or markedly reduced arrhythmias in a subgroup of CPVT1 patients with specific RyR2 mutations. The gene discussed is RYR2; the disease is Arrhythmia.